Yes, that might be outdated.
Then again, if only one CPACS drug exists, i.e. bisantrene, it's true that being an FTO inhibitor is a necessary but not sufficient condition for being CPACS. But, depending on the actual CP MOA, that might just be a concidence rather than a useful insight.
e.g. one might as well say that a necessary but not sufficent condition for being CPACS is that the first letter of the drug's name is "b".
PS. How did we manage before @LongTony invented CPACS?
Speculative M&A Transaction Analysis, page-741
-
- There are more pages in this discussion • 35 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.66 |
Change
-0.020(1.19%) |
Mkt cap ! $282.8M | |||
| Open | High | Low | Value | Volume |
| $1.68 | $1.68 | $1.61 | $118.5K | 72.33K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $1.65 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.66 | 601 | 1 |
View Market Depth
| Last trade - 16.10pm 04/09/2024 (20 minute delay) ? |
| RAC (ASX) Chart |